^
Association details:
| Biomarker: | CD33 expression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Actimab-A (lintuzumab-Ac225) (α radiation emission, CD33-targeted antibody- radioimmunoconjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sequential Salvage Chemotherapy and Lintuzumab‑Ac225 in Relapsed/Refractory AML Results in Deep Responses and Prolonged Survival in Adverse Risk Acute Myeloid Leukemia (AML) and in AML Patients that Received Prior Venetoclax Therapy
Published date:
09/01/2023
Excerpt:
This Phase I study enrolled R/R AML fit pts, with CD33 expression on >25% of leukemic blasts….The trial enrolled 4 cohorts with Lintuzumab-Ac225 at doses ranging from 0.25 uCi/kg to 1.0 uCi/kg.For high-risk patients, 42% (n=8) of patients achieved CRc (CR+CRi), and 16% (n=3) achieved MLFS, for an overall response rate (ORR) of 58%. Among patients achieving CRc, 71% achieved MRD negativity by flow cytometry. In all high-risk patients, the median OS was 7.3 months…CLAG-M followed by Lintuzumab-Ac225 yielded significantly better clinical outcomes in high-risk populations, particularly in patients previously treated with venetoclax combinations.
Secondary therapy:
CLAG
